CHRM1

Across TCGA pan-cancer cohorts, CHRM1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CHRM1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CHRM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRM1 expression acts as an unfavorable survival marker.

READ, ESCA, and THYM are the cancer types where CHRM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.059	0.845	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
THYM	OS	Median	All	0.352	0.884	<.001	8	view →
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	II,III,IV	0.140	0.743	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CHRM1–READ (DFS)

Open the READ breakdown →